Page last updated: 2024-12-09

1-[1-(4-fluorophenyl)-2,5-dimethyl-3-pyrrolyl]-2-(4-methyl-1-piperidinyl)ethanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're asking about a specific chemical compound, **1-[1-(4-fluorophenyl)-2,5-dimethyl-3-pyrrolyl]-2-(4-methyl-1-piperidinyl)ethanone**. It's a complex molecule with a long and descriptive name, but here's a breakdown of its importance in research:

**What it is:**

* **Structure:** This compound has a central core of a pyrrole ring (a 5-membered ring containing nitrogen).
* Attached to the pyrrole ring:
* A fluorophenyl group (a benzene ring with a fluorine atom attached)
* Two methyl groups (CH3)
* Attached to the pyrrole ring through an ethanone group (a ketone)
* A 4-methylpiperidinyl group (a 6-membered ring with a nitrogen atom and a methyl group).

* **Chemical properties:** It's likely this compound is organic (carbon-based) and may have a variety of properties depending on its specific functional groups.

**Why it's important in research:**

Without more information about this specific compound, it's impossible to say definitively why it's important for research. However, given its structure, it could be significant for several reasons:

* **Potential pharmaceutical activity:** Many organic compounds with specific functional groups and arrangements have biological activity. This compound's structure suggests it could interact with biological targets and potentially be used as a drug or lead compound.
* **Material science:** Organic compounds with specific functional groups can be used as building blocks for polymers, plastics, and other materials. This compound's structure might make it suitable for use in materials science.
* **Chemical synthesis:** It might be a key intermediate or reagent in the synthesis of other more complex molecules of interest in research.

**To know more, you'd need additional information:**

* **Who is researching it?** Knowing the research group or area of focus can provide insight.
* **What is its purpose?** Is it being tested for a specific biological effect, or being used to develop new materials?
* **What are its properties?** Understanding its solubility, stability, reactivity, etc., helps understand its potential applications.

**Where to find more information:**

* **Scientific databases:** PubMed, SciFinder, and Google Scholar can be used to search for published research on this specific compound.
* **Research publications:** If you know a specific research group studying this compound, you can look for their publications.

Remember, research is an ongoing process, and understanding the importance of a compound often requires context.

Cross-References

ID SourceID
PubMed CID675433
CHEMBL ID1498085
CHEBI ID120779
SCHEMBL ID6922952

Synonyms (16)

Synonym
CCG-190729
HMS2614J21
smr000265062
MLS000418514 ,
CHEBI:120779
AKOS000811298
1-[1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl]-2-(4-methylpiperidin-1-yl)ethanone
SCHEMBL6922952
325742-01-6
F1142-1243
1-(1-(4-fluorophenyl)-2,5-dimethyl-1h-pyrrol-3-yl)-2-(4-methylpiperidin-1-yl)ethanone
CHEMBL1498085
Q27208920
1-[1-(4-fluorophenyl)-2,5-dimethyl-3-pyrrolyl]-2-(4-methyl-1-piperidinyl)ethanone
Z55144144
1-[1-(4-fluorophenyl)-2,5-dimethyl-1h-pyrrol-3-yl]-2-(4-methylpiperidin-1-yl)ethan-1-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrrolesAn azole that includes only one N atom and no other heteroatom as a part of the aromatic skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency9.52830.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency12.58930.01846.806014.1254AID624417
BRCA1Homo sapiens (human)Potency0.79430.89137.722525.1189AID624202
ATAD5 protein, partialHomo sapiens (human)Potency7.75360.004110.890331.5287AID504466; AID504467
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686979
P53Homo sapiens (human)Potency10.00000.07319.685831.6228AID504706
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency89.12510.035520.977089.1251AID504332
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency2.23870.01262.451825.0177AID485313
ras-related protein Rab-9AHomo sapiens (human)Potency1.41250.00022.621531.4954AID485297
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency22.74070.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency12.99530.004611.374133.4983AID624296
survival motor neuron protein isoform dHomo sapiens (human)Potency12.58930.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]